e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Hot topics on airway diseases: new horizons in treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials
Noel Gerard McElvaney (Dublin, Ireland), N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, Robert Sandhaus, Oliver Vit, Michael Fries, Jonathan M. Edelman
Source:
International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Session:
Hot topics on airway diseases: new horizons in treatment
Session type:
Oral Presentation
Number:
285
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Noel Gerard McElvaney (Dublin, Ireland), N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, Robert Sandhaus, Oliver Vit, Michael Fries, Jonathan M. Edelman. LATE-BREAKING ABSTRACT: Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials. Eur Respir J 2015; 46: Suppl. 59, 285
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Long-term efficacy of A
1
-PI therapy in RAPID and its extension study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Safety of biweekly a
1
-antitrypsin treatment in the RAPID programme
Source: Eur Respir J, 52 (5) 1800897; 10.1183/13993003.00897-2018
Year: 2018
LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Effect of exacerbations on lung density in alpha-1 antitrypsin deficiency: Subgroup analysis of the RAPID trial programme
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
LATE-BREAKING ABSTRACT: The REACH study, a randomized controlled trial assessing the safety and effectiveness of the spiration valve system intra-bronchial therapy for severe emphysema
Source: International Congress 2016 – Advancements in bronchoscopy
Year: 2016
LATE-BREAKING ABSTRACT: The RENEW trial: Predictors of effectiveness of endobronchial coil therapy in patients with advanced emphysema
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014
LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006
Late Breaking Abstract - RECEIVER trial: sustained use and improved outcomes with digitally supported COPD co-management
Source: Virtual Congress 2021 – E-health for COVID-19
Year: 2021
LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept